499 related articles for article (PubMed ID: 15894465)
1. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
Bedenic B; Vranes J; Suto S; Zagar Z
Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
[TBL] [Abstract][Full Text] [Related]
3. [Effect of broad spectrum beta-lactamases on in vitro sensitivity of clinical isolates of Klebsiella pneumoniae to oral cephalosporins].
Bedenić B; Singer S
Lijec Vjesn; 2000; 122(1-2):8-13. PubMed ID: 10916350
[TBL] [Abstract][Full Text] [Related]
4. Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases.
Sougakoff W; Jarlier V
J Antimicrob Chemother; 2000 Sep; 46 Suppl 1():9-14; discussion 63-5. PubMed ID: 11051618
[TBL] [Abstract][Full Text] [Related]
5. Defining an extended-spectrum beta-lactamase.
Livermore DM
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():3-10. PubMed ID: 18154524
[TBL] [Abstract][Full Text] [Related]
6. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
[TBL] [Abstract][Full Text] [Related]
7. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
Livermore DM; Mushtaq S; Nguyen T; Warner M
Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
[TBL] [Abstract][Full Text] [Related]
8. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex beta-lactamase patterns including extended-spectrum enzymes.
Segatore B; Setacci D; Perilli M; Franchino L; Franceschini N; Agnifili A; Rossolini GM; Amicosante G
Int J Antimicrob Agents; 2004 May; 23(5):480-6. PubMed ID: 15120727
[TBL] [Abstract][Full Text] [Related]
10. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia.
Palasubramaniam S; Muniandy S; Navaratnam P
J Microbiol Immunol Infect; 2009 Apr; 42(2):129-33. PubMed ID: 19597644
[TBL] [Abstract][Full Text] [Related]
11. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
[TBL] [Abstract][Full Text] [Related]
12. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
[TBL] [Abstract][Full Text] [Related]
13. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
Shah AA; Hasan F; Ahmed S; Hameed A
Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli.
Puerto AS; Fernández JG; del Castillo Jde D; Pino MJ; Angulo GP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):135-9. PubMed ID: 16406187
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity and specificity of various beta-lactam antibiotics and phenotypical methods for detection of TEM, SHV and CTX-M extended-spectrum beta-lactamases.
Bedenic B; Vranes J; Mihaljevic Lj; Tonkic M; Sviben M; Plecko V; Kalenic S
J Chemother; 2007 Apr; 19(2):127-39. PubMed ID: 17434820
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum beta-lactamases.
Turner PJ
Clin Infect Dis; 2005 Aug; 41 Suppl 4():S273-5. PubMed ID: 16032564
[TBL] [Abstract][Full Text] [Related]
19. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
Bedenić B
Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890
[TBL] [Abstract][Full Text] [Related]
20. Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China.
Yu Y; Ji S; Chen Y; Zhou W; Wei Z; Li L; Ma Y
J Infect; 2007 Jan; 54(1):53-7. PubMed ID: 16533535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
